Research & Publications
CAR T-Cell Access in Relapsed/Refractory LBCL Patients
Summary
Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking treatment that can offer long-term remission for some patients with relapsed or treatment-resistant large B-cell lymphoma (LBCL), a fast-growing and difficult-to-treat blood cancer. However, not all eligible patients are able to access this potentially life-saving therapy.
In this national study of more than 5,000 patients with relapsed or refractory LBCL, researchers investigated how demographic factors, social conditions, and distance from approved treatment centers affect access to CAR T-cell treatment.
The study found that older adults, women, Black patients, and those with lower incomes were significantly less likely to receive CAR T therapy. Patients who lived two to four hours from a treatment center were also less likely to get therapy, while those living more than four hours away were not significantly different from those living within 2 hours of a treatment center, possibly due to travel support or availability of alternative living arrangements (e.g., family) near more distant treatment centers.
Interestingly, patients with more complex health conditions were more likely to receive CAR T-cell therapy, possibly because they were not considered good candidates for other treatments such as stem cell transplants, which are more likely to lead to adverse side effects than CAR T.
Why This Matters
Despite the promise of CAR T-cell therapy, serious barriers to access remain based on age, race, income, sex, and geography. These findings highlight the need for targeted solutions, such as expanding financial support, improving provider education, addressing systemic bias, and increasing the number of treatment centers. Ensuring equitable access to innovative therapies like CAR T is essential to improving outcomes for all patients.
Read the Full Study:
